Comprehensive Molecular Diagnostics for CML and MPN

PRECIPIO EXPECT MORE.

Comprehensive CML and MPN molecular work-ups for a more informed patient status.

BCR:ABL1 Panel:

PRECIPIO
p190 p210 p203 p230

Other Labs
p190 p210

4 Breakpoint detection for broader coverage and **0.001% IS sensitivity** for superior diagnostics in initial work-ups and MRD monitoring.

BCR-ABL1
- p210
- p190
- p230
- p203

ABL1 Resistance Panel:

Treatment
- Tier 1
- Tier 2
- Tier 3

For **BCR::ABL1 positive** patients, our ABL1 Resistance Panel detects ABL1 gene mutations associated with **therapy resistance** and **early relapse.**

ABL1 Resistance
- Exon 4
- Exon 5
- Exon 6
- Exon 7
- Exon 8

MPN Panel:

PRECIPIO
JAK2 V617F
JAK2 Ex 12
JAK2 Ex 13
MPL
CALR

Other Labs
JAK2 V617F
JAK2 Exon 12
MPL/CALR

For driver mutation status, including **co-expressions**, helping you make more informed treatment decisions that single gene reflex testing can miss.

MPN
- JAK2 V617F
- JAK2 Exon 12
- JAK2 Exon 13
- MPL
- CALR

CML/MPN Algorithm

5ml Lavendar
- (+) BCR-ABL1
- (-) BCR-ABL1, Rule Out MPN

For more information please contact:
contact@precipiodx.com | www.precipiodx.com | Tel: +1.203.787.7888

rev.2311

PRECIPIO EXPECT MORE.

Efficient, Actionable Molecular Diagnostics for AML, CLL & Cytopenia

PRECIPIO
EXPECT MORE.

Cytopenia Panel:
### Aid In CHIP & Early MDS Diagnosis/Prognosis From Peripheral Blood

Minimally invasive sampling to aid in the diagnosis and prognosis of **CHIP** and **early MDS**. **No bone marrow required**.

CYTOPENIA

- ASXL1
- SF3B1
- DNMT3A
- RUNX1
- WT1

CHIP

MDS

AML Panel:
Same-Day Panel Results to Guide Time-Sensitive Treatment Decisions

Therapeutic targets run in parallel for **rapid**, comprehensive molecular profiles that enable you to **determine the RIGHT treatment RIGHT away**.

AML

- IDH1 / IDH2
- KIT
- FLT3
- NPM1
- CEBPA

CLL Panel:
Comprehensive Prognostic Insight

Prognostic panel to aid in patient treatment decisions from non-intervention to aggressive therapies.

CLL

- CXCR4
- NOTCH1
- MYD88
- SF3B1

Cytopenia, AML, and CLL molecular panels have been validated as lab developed tests at Precipio. They have not been approved by the FDA.

For more information please contact:
contact@precipiodx.com | www.precipiodx.com | Tel: +1.203.787.7888

rev.2311

PRECIPIO
EXPECT MORE.